The IPO Buzz: Accelevation (ACCV) Prices IPO at $18 – $2 Below Range
Accelevation Holdings (ACCV) priced its IPO at $18.00 – $2.00 below range – and sold 30 million shares – the number of shares in the prospectus – to raise $540 million on Tuesday night, Sept. 29, 2026. At pricing, Accelevation has a market cap of $4.03 billion.
Accelevation’s stock is expected to start trading tomorrow – Wednesday, Sept. 30, 2026 – on the NASDAQ.
Morgan Stanley and J.P. Morgan served as the lead joint book-runners. Goldman Sachs, Barclays and BofA Securities were joint book-runners.
Accelevation designs, manufactures and installs power distribution and infrastructure products for data centers.
Olympus Partners, a private equity firm, owns Accelevation – and it will still control the company after the IPO.
Accelevation is going public at a time of strong pushback against AI data centers, which represent a major segment of Accelevation’s clientele.
Accelevation Holdings, based in Miamisburg, near Dayton, Ohio, described its products in the prospectus:
-Its power products include branch circuit whips and high-density remote power panels as well as power distribution units, related monitoring technologies and adjacent upstream power distribution products.
-Its infrastructure products include TechFrame steel structures, conveyance systems, rack and cabinet support, cable and fiber routing components and other modular infrastructure components.
-Its thermal management products include containment, airflow management and liquid-cooling-ready products integrated into white space infrastructure systems.
Accelevation’s customers include AWS (Amazon Web Services), CoreWeave, CyrusOne, Digital Realty, Google, Meta, Forgent Power Solutions and Microsoft, according to published reports.
“We help our large data center customers, including AI and cloud data center customers, accelerate deployment through integrated factory-built solutions designed for speed, scalability and deployment certainty,” the company said in the prospectus. “Our execution against these customer needs drove revenue growth of 147 percent from 2024 to 2025 and contributed to a backlog of about $1.1 billion as of June 30, 2026.”
Accelevation plans to use its proceeds to repay about $180 million of debt, the prospectus said.
Accelevation is profitable: Net income of $32.36 million on revenue of $726.64 million for the 12 months that ended on June 30, 2026, according to financial statements in the prospectus.
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Source: https://www.iposcoop.com/the-ipo-buzz-accelevation-accv-proposed-prices-ipo-at-18-2-below-range/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

